(Reuters) - PreMD shares were up 77 Canadian cents, or 67 percent, at
C$1.92 at midafternoon on the Toronto Stock Exchange.
The deal gives AstraZeneca the exclusive right to market
and distribute Prevu, a skin cholesterol test to help assess an
individual's risk of coronary heart disease, in the United
States.
Read more at Reuters.com Government Filings News
C$1.92 at midafternoon on the Toronto Stock Exchange.
The deal gives AstraZeneca the exclusive right to market
and distribute Prevu, a skin cholesterol test to help assess an
individual's risk of coronary heart disease, in the United
States.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment